Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain AMGN message board posts where the ticker symbol AMGN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest AMGN SEC Filings

Filings Format Description Filing Date File/Film Number
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001127602-18-027371 Size: 4 KB
2018-09-11
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-025351 Size: 8 KB
2018-08-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-024774 Size: 5 KB
2018-08-06
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001127602-18-024510 Size: 12 KB
2018-08-02
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-024509 Size: 6 KB
2018-08-02
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-024508 Size: 5 KB
2018-08-02
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-024507 Size: 5 KB
2018-08-02
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-024506 Size: 5 KB
2018-08-02
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-024505 Size: 6 KB
2018-08-02
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000318154-18-000015 (34 Act)  Size: 11 MB
2018-07-27 001-37702
18972830
More AMGN SEC Filings


Related news from
Fri, 12 Oct 2018
13:23:01 +0000
AbbVie Settles With Novartis to Delay Humira Biosimilar in US
AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.
Thu, 11 Oct 2018
22:01:13 +0000
Abbvie settles Humira patent disputes with Novartis unit
Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira. Abbvie, however, did not disclose details regarding the royalties it will receive from Novartis generics unit, Sandoz, as part of the agreement. Shares of Abbvie rose 2.39 percent to $92.87 in after-market trading.
Thu, 11 Oct 2018
19:02:00 +0000
Here's Why Coherus BioSciences Fell 18.1% in September
Enthusiasm for the biopharma is wearing off despite its announcement of an important commercial milestone.
Thu, 11 Oct 2018
17:41:00 +0000
Here's Why bluebird bio Dropped 13.3% in September
The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.
Thu, 11 Oct 2018
12:01:12 +0000
Healthcare Stocks in the Red amid Broader Market Sell-Off
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
Wed, 10 Oct 2018
15:05:02 +0000
Celgene: Multiple Myeloma Franchise Could Drive Growth
How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).
Wed, 10 Oct 2018
13:57:01 +0000
Tilary Buys Alef Biotechnology to Build Base in Latin America
Tilary (TLRY) acquires import and distribution partner, Alef Biotechnology to strengthen its base in Latin America.
Wed, 10 Oct 2018
13:35:02 +0000
Celgene: Analysts’ Views before Its Third-Quarter Earnings
Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.
Tue, 09 Oct 2018
20:19:08 +0000
FDA Sets Action Date for Recro's Pain Management Candidate
The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.
Tue, 09 Oct 2018
19:12:32 +0000
10 S&P 500 Stocks to Buy for the Long Term
The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren’t sure what the foreseeable future holds. In simplest terms, it’s just plain stressful.
Tue, 09 Oct 2018
14:21:02 +0000
Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis
Bausch receives tentative FDA approval for the NDA for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients.
Tue, 09 Oct 2018
11:32:17 +0000
Analysts Are Mostly Positive on Neurocrine Biosciences
Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.
Mon, 08 Oct 2018
12:01:00 +0000
Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?
A market beatdown following some good news has investors scratching their heads.
Mon, 08 Oct 2018
12:00:09 +0000
See what the IHS Markit Score report has to say about Amgen Inc.
Amgen Inc NASDAQ/NGS:AMGN
Fri, 05 Oct 2018
22:49:00 +0000
Cramer's lightning round: Watch out—momentum stocks are out of favor right now
Jim Cramer rattles off his take on callers' favorite stocks, including a DNA sequencing play that's been dragged down by the sell-off.
Fri, 05 Oct 2018
22:49:00 +0000
Cramer's lightning round: Watch out—momentum stocks are out of favor right now
Jim Cramer rattles off his take on callers' favorite stocks, including a DNA sequencing play that's been dragged down by the sell-off.
Thu, 04 Oct 2018
22:22:45 +0000
Amgen: Compelling Valuation
Analyzing the investment prospects of this biotech company
Thu, 04 Oct 2018
14:31:25 +0000
Amgen’s Stock Performance and Estimates after Q3 2018
Amgen (AMGN) is a biotechnology company that focuses on discovering, developing, and delivering drugs in therapeutic areas such as cardiovascular, neuroscience, and oncology. The chart below compares Amgen’s EPS and revenues since the first quarter of 2017, as well as its third-quarter estimates.
Thu, 04 Oct 2018
11:31:14 +0000
Ionis Pharmaceuticals’ Revenue Stream
Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.
Thu, 04 Oct 2018
07:20:06 +0000
Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US
Competition from manufacturers of biosimilar drugs, or follow-on versions of complex biotech drugs, is a rising threat for branded pharmaceutical companies, Moody's Investors Service says in a new report. Branded drug makers including Roche Holding AG, Amgen Inc., AbbVie Inc. and Johnson & Johnson will see declining sales of some of their best-selling drugs over the next 12 to 18 months.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "It [ValueForum] has provided me with eye opening information on a wide scale. The collective wisdom of the membership is astounding and somewhat intimidating; but useful input is appreciated pretty universally." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards